Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 10Active not recruiting 9Completed 6Unknown 4Terminated 3Not yet recruiting 1Approved for marketing 1

Sponsor Class

OTHER 7INDUSTRY 6

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Genitourinary 6

Conditions

Neoplasms 1905Breast Neoplasms 1426Carcinoma, Non-Small-Cell Lung 1179Prostatic Neoplasms 740Colorectal Neoplasms 686Neoplasm Metastasis 624Multiple Myeloma 548Melanoma 529Ovarian Neoplasms 456Lung Neoplasms 447Lymphoma, Non-Hodgkin 385Recurrence 374Lymphoma 374Leukemia, Myeloid, Acute 370Pancreatic Neoplasms 358Carcinoma, Renal Cell 339Carcinoma, Hepatocellular 286Stomach Neoplasms 281Leukemia, Lymphocytic, Chronic, B-Cell 268Lymphoma, Follicular 254Head and Neck Neoplasms 246Glioblastoma 220Leukemia 215Small Cell Lung Carcinoma 183Lymphoma, Large B-Cell, Diffuse 183Squamous Cell Carcinoma of Head and Neck 181Urinary Bladder Neoplasms 175Carcinoma 175Uterine Cervical Neoplasms 174Advanced Solid Tumors 161

Interventions

radium Ra 223 dichloride 1olaparib 1enzalutamide 1afuresertib 1Prednisone 1Clinical Trials, Phase I as Topic 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Metastatic Castration-resistant Prostate Cancer × Clear all
NCT02141438 2025-10-16

REASSURE

Bayer

Completed
1,472 enrolled 18 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04060394 2024-10-10

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Laekna Limited

Phase 1/2 Completed
49 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05252364 2024-03-21

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

Hinova Pharmaceuticals Inc.

Phase 1 Completed
22 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT02987543 2023-10-06

Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

AstraZeneca

Phase 3 Completed
387 enrolled 16 charts 1 FDA
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05725070 2023-10-06

Phase 0/1 Study of 212Pb-NG001 in mCRPC

ARTBIO Inc.

Phase EARLY_PHASE1 Completed
3 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04268628 2022-01-03

EXPLORE

Janssen-Cilag Farmaceutica Ltda.

Completed
42 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡